Twenty‐four‐week efficacy and safety of switching virologically suppressed HIV‐1‐infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION)
暂无分享,去创建一个
K. Arastéh | A. Quinson | J. Livrozet | J. Guo | C. Orkin | Douglas J. Ward | Andreas Plettenberg | Christiane Cordes | Elaine Wang | Chan-Loi Yong | Patrick A. Robinson